Edwards Lifesciences Corporation $EW Shares Purchased by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC increased its holdings in Edwards Lifesciences Corporation by 38.3%, owning 200,819 shares valued at approximately $14.6 million.
• Edwards Lifesciences reported earnings of $0.67 per share, surpassing analysts' estimates, with a revenue of $1.53 billion, up 11.9% year-over-year.
• Institutional investors own 79.46% of Edwards Lifesciences, reflecting significant interest from the investment community, while the stock price has seen a marginal decline of 0.1% recently.

Parkman Healthcare Partners LLC increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 38.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 200,819 shares of the medical research company's stock after purchasing an additional 55,605 shares during the quarter. Edwards Lifesciences accounts for about 1.7% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 22nd largest holding. Parkman Healthcare Partners LLC's holdings in Edwards Lifesciences were worth $14,555,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Edwards Lifesciences by 8.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock worth $482,621,000 after purchasing an additional 513,468 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in Edwards Lifesciences by 24.9% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 4,615,163 shares of the medical research company's stock worth $341,661,000 after purchasing an additional 921,500 shares during the period. Nuveen LLC bought a new position in Edwards Lifesciences in the first quarter worth about $330,881,000. Finally, Invesco Ltd. lifted its holdings in Edwards Lifesciences by 2.6% in the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company's stock worth $310,773,000 after acquiring an additional 107,241 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,014 shares of company stock worth $1,698,844. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $0.37 during midday trading on Tuesday, reaching $79.84. 2,415,522 shares of the company traded hands, compared to its average volume of 3,543,293. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The stock has a 50-day moving average price of $78.86 and a 200 day moving average price of $75.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a market cap of $46.87 billion, a price-to-earnings ratio of 11.49, a PEG ratio of 3.87 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the previous year, the business earned $0.70 earnings per share. The company's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on EW shares. Evercore ISI raised their target price on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a report on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft raised their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Finally, Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.